Tian  Chen

Jilin Beodo Medical Immunization Products Co., Ltd., Jilin, 132013, Jilin, China
Author    Correspondence author
Journal of Vaccine Research, 2024, Vol. 14, No. 2   
Received: 12 Mar., 2024    Accepted: 15 Apr., 2024    Published: 25 Apr., 2024

This is an open access article published under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Antimicrobial resistance (AMR) poses a significant threat to global health, leading to increased morbidity, mortality, and healthcare costs. Traditional approaches to combat AMR, such as antibiotic stewardship and the development of new antibiotic, have proven insufficient. Vaccines offer a promising alternative by preventing infections and reducing the need for antibiotics. This study explores the role of vaccination strategies in mitigating antimicrobial resistance from a global perspective, highlighting the current state of vaccine development, their impact on AMR, and the challenges and future prospects in this field. The results showed that vaccines have demonstrated substantial efficacy in reducing the incidence of infections and subsequent antibiotic use, thereby decreasing the emergence of AMR. For instance, the introduction of pneumococcal conjugate vaccines (PCV) in Ethiopia has significantly slowed the development of AMR, reducing antimicrobial treatment failures and AMR-related deaths. Existing vaccines, such as those for Haemophilus influenzae type B and Streptococcus pneumoniae, have shown impressive results in reducing antibiotic use and AMR. Furthermore, novel vaccine technologies, including virus-like particles (VLPs), offer promising avenues for future vaccine development against AMR-related pathogens. Vaccination strategies play a crucial role in the global fight against antimicrobial resistance. By preventing infections and reducing antibiotic use, vaccines can significantly mitigate the development and spread of AMR. Continued investment in vaccine research and development, along with international collaboration, is essential to harness the full potential of vaccines in combating AMR.

Antimicrobial resistance; Vaccines; Pneumococcal conjugate vaccine; Virus-like particles; Global health; Antibiotic use; Vaccine development